Skip to main navigation
Skip to search
Skip to main content
Experts@Minnesota Home
Search content at Experts@Minnesota
Home
Profiles
Research units
University Assets
Projects and Grants
Research output
Datasets
Press/Media
Activities
Fellowships, Honors, and Prizes
Impacts
PD-1 pathway inhibitors: Changing the landscape of cancer immunotherapy
Dawn E. Dolan
, Shilpa Gupta
Medicine - Hematology, Oncology, Transplant
Research output
:
Contribution to journal
›
Article
›
peer-review
123
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'PD-1 pathway inhibitors: Changing the landscape of cancer immunotherapy'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Pathway Inhibitors
100%
Cancer Immunotherapy
100%
Programmed death-1 Pathway
100%
Anti-programmed Cell Death Protein 1 (anti-PD-1)
100%
Anti-programmed death-1
100%
Tumor
75%
Programmed Death-ligand 1 (PD-L1)
75%
Programmed Cell Death Protein 1 (PD-1)
50%
Hematological Malignancies
25%
Durable Response
25%
Therapeutic Target
25%
Drug Development
25%
Lung Cancer
25%
Signaling Pathway
25%
Targeted Therapy
25%
Poor Prognosis
25%
Cytotoxic Chemotherapy
25%
Cancer Treatment
25%
Oncology
25%
Immunotherapeutics
25%
Safety Profile
25%
Melanoma
25%
Checkpoint Inhibitors
25%
Kidney Cancer
25%
American Society of Clinical Oncology
25%
MEDLINE
25%
Immunotherapeutic Approaches
25%
PubMed
25%
Good Safety
25%
Checkpoint Activation
25%
Stopping Therapy
25%
Tumor-induced Immune Suppression
25%
Pathways in Cancer
25%
Immune Destruction
25%
Immune Checkpoint Therapy
25%
Malignant Solid Tumor
25%
In-depth Literature Review
25%
Promising Therapeutics
25%
Early Clinical Experience
25%
Medicine and Dentistry
Programmed Death-Ligand 1
100%
Cancer Immunotherapy
100%
Tumor
42%
Malignant Neoplasm
28%
Oncology
14%
Lung Cancer
14%
Neoplasm
14%
Cancer
14%
Targeted Therapy
14%
Solid Malignant Neoplasm
14%
Immunosuppressive Treatment
14%
Hematologic Malignancy
14%
Clinical Oncology
14%
Cancer Treatment
14%
Cytotoxic Chemotherapy
14%
Kidney Cancer
14%
Programmed Death 1 Receptor
14%
Immunotherapy
14%
Signal Transduction
14%
Melanoma
14%
Checkpoint Signalling
14%
Therapeutic Target
14%